CCM
ENTA icon

Camber Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Camber Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-110,000
Closed -$5.12M – 42
2022
Q4 		$5.12M Buy
+110,000
New +$5.01M 0.18% 39

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Camber Capital Management's ENTA Position: Q1 2023 in Review

Camber Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2023, closing a stake of 110,000 shares — an estimated $5.12M sold.

Camber Capital Management first reported a position in ENTA in Q4 2022 and held it in 1 quarter. The position peaked at $5.12M in Q4 2022. 144 funds tracked by Wall St. Rank hold ENTA as of Q1 2023.

  • Camber Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Camber Capital Management sold 110,000 Enanta Pharmaceuticals shares in Q1 2023, an estimated $5.12M.
  • Camber Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Camber Capital Management's Enanta Pharmaceuticals position peaked at $5.12M in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2023.

Based on Camber Capital Management's 13F filing for Q1 2023, filed 15 May 2023.